Mafalda Oliveira, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, provides an overview of the Phase II SERENA-2 (NCT04214288) trial investigating camizestrant, a next generation oral SERD versus fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer. The primary objective was to determine clinical efficacy of camizestrant versus fulvestrant by investigator-assessed progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), response duration, clinical benefit rate (CBR) at 24 weeks, overall-survival (OS) and safety. To assess the impact of prior CDK4/6 inhibitor (CDK4/6i) treatment, randomization was stratified so that 50% of patients had prior CDK4/6i. 2/3 of patients had lung or liver metastasis and 20% of patients had prior chemotherapy in the metastatic. 35-40% of patients had a detectable ESR1 mutations at baseline. 75 mg and 150 mg of camizestrant had an improved PFS compared to fulvestrant that was statistically significant and clinically meaningful. Camizestrant was well tolerated.This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
